Physician profile
Thomas C Walbridge
NPI 1710414180
$1,127.46
in general payments reported to CMS, 2019-2025
24 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $67.78 · 2021: $125 · 2022: $349 · 2023: $211 · 2024: $123 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $190.75 | 2021-2024 | Trelegy Ellipta |
| Abbvie INC. | $168.40 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $96.85 | 2022-2025 | Airsupra, Nexium, Breztri |
| Pfizer INC. | $76.73 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $62.27 | 2021-2025 | Rexulti |
| Novo Nordisk INC | $61.52 | 2021-2022 | |
| Lilly USA, LLC | $43.45 | 2022-2025 | Zepbound, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.90 | 2022 | |
| Horizon Therapeutics Plc | $39.51 | 2021-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $39.15 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.16 | 2022 | |
| Allergan, INC. | $37.13 | 2020 | |
| Jazz Pharmaceuticals INC. | $28.19 | 2022 | |
| Sumitomo Pharma America, INC. | $24.67 | 2024 | Gemtesa |
| Boston Scientific Corporation | $24.41 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $24.26 | 2021 | |
| Amarin Pharma, INC. | $19.28 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.17 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $17.83 | 2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $17.19 | 2023 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $16.42 | 2023 | Eliquis |
| Corium, LLC | $15.70 | 2023 | Azstarys |
| Astellas Pharma US INC | $14.15 | 2024 | Veozah |
| Collegium Pharmaceutical, INC. | $11.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Walbridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.